Fas cell surface death receptor controls hepatic lipid metabolism by regulating mitochondrial function

Johan Auwerx, Vera Monica Lemos Da Silva, Eija Riitta Pirinen, Matthias Alexander Sokrates Stein
2017
Article

Résumé

Nonalcoholic fatty liver disease is one of the most prevalent metabolic disorders and it tightly associates with obesity, type 2 diabetes, and cardiovascular disease. Reduced mitochondrial lipid oxidation contributes to hepatic fatty acid accumulation. Here, we show that the Fas cell surface death receptor (Fas/CD95/Apo-1) regulates hepatic mitochondrial metabolism. Hepatic Fas overexpression in chow-fed mice compromises fatty acid oxidation, mitochondrial respiration, and the abundance of mitochondrial respiratory complexes promoting hepatic lipid accumulation and insulin resistance. In line, hepatocyte-specific ablation of Fas improves mitochondrial function and ameliorates high-fat-diet-induced hepatic steatosis, glucose tolerance, and insulin resistance. Mechanistically, Fas impairs fatty acid oxidation via the BH3 interacting-domain death agonist (BID). Mice with genetic or pharmacological inhibition of BID are protected from Fas-mediated impairment of mitochondrial oxidation and hepatic steatosis. We suggest Fas as a potential novel therapeutic target to treat obesity-associated fatty liver and insulin resistance.

Official source

https://infoscience.epfl.ch/record/232346?ln=fr

À propos de ce résultat

Cette page est générée automatiquement et peut contenir des informations qui ne sont pas correctes, complètes, à jour ou pertinentes par rapport à votre recherche. Il en va de même pour toutes les autres pages de ce site. Veillez à vérifier les informations auprès des sources officielles de l'EPFL.

Concepts associés

Chargement

Publications associées

Chargement

Overweight and obesity are increasingly common public health issues worldwide, leading to a wide range of diseases from metabolic syndrome to steatohepatitis and cardiovascular diseases. While the increase in the prevalence of obesity is partly attributable to changes in lifestyle (i.e. increased sedentarity and changes in eating behaviour), the metabolic and clinical impacts of these obesogenic conditions varies between sexes and genetic backgrounds. The conception of personalised treatments of obesity and its complications require a thorough understanding of the diversity of responses to environmental stimuli such as high-fat diet intake. In this thesis, by analysing nine genetically diverse mouse strains, we show that much like humans, mice respond to high-fat diet in a genetic- and sex-dependent manner. Physiological and molecular responses to high-fat diet are associated with the expression of genes involved in immunity and mitochondrial function. Finally, we find that mitochondrial function and mitochondrial supercomplex assembly may explain part of the diversity of physiological responses. By exploring the complex interactions between genetics and metabolic phenotypes via gene expression and molecular traits, we shed light on the importance of genetic background and sex in determining metabolic outcomes. In addition to providing the community with an extensive resource for optimizing future experiments, this work serves as an exemplary design for more generalizable translational studies.

EPFL2021

Chargement

Transporters of the SLC25 mitochondrial carrier superfamily bridge cytoplasmic and mitochondrial metabolism by channeling metabolites across mitochondrial membranes and are pivotal for metabolic homeostasis. Despite their physiological relevance as gatekeepers of cellular metabolism, most of the SLC25 family members remain uncharacterized. During my PhD studies, I investigated the function of SLC25A47, an orphan carrier uniquely expressed in hepatocytes. We used a murine loss-of-function (LOF) model to unravel the role of this transporter in mitochondrial and hepatic homeostasis. Slc25a47hep-/- mice displayed a wide variety of metabolic abnormalities, as a result of sustained energy deficiency in the liver originating from impaired mitochondrial respiration in this organ. This mitochondrial phenotype was associated with a robust activation of the mitochondrial stress response (MSR) in the liver, which in turn, induced the secretion of several mitokines, amongst which FGF21 played a preponderant role in the translation of the effects of the MSR on systemic physiology. To dissect the FGF21-dependent and -independent physiological changes induced by the loss of Slc25a47, we generated a double Slc25a47-Fgf21 LOF mouse model, and demonstrated that several aspects of the hypermetabolic state were entirely driven by hepatic secretion of FGF21. On the other hand, the metabolic fuel inflexibility induced by loss of Slc25a47 could not be rescued by genetic removal of Fgf21. Finally, we challenged Slc25a47hep-/- mice with high-fat high-sucrose (HFHS) diet and observed the development of liver fibrosis.Collectively, the data presented in this thesis show that SLC25A47 is a novel determinant of hepatic metabolism and place this carrier at the center of mitochondrial homeostasis.

EPFL2022

Chargement

Discovered in the beginning of the 20th century, nicotinamide adenine dinucleotide (NAD+) has evolved from a simple oxidoreductase cofactor to being an essential cosubstrate for a wide range of regulatory proteins that include most notoriously the sirtuin family of NAD+-dependent protein deacylases. Altered NAD+ metabolism is associated with many pathological conditions, including aging and obesity, while beneficial effects of increased NAD+ levels and subsequent sirtuin activation have been established across many different species. Due to their capacity to ameliorate mitochondrial homeostasis, organismal metabolism and lifespan, strategies aiming to boost NAD+ content possess a high therapeutic potential. This thesis describes a novel approach to increase NAD+ levels by stimulating its de novo biosynthesis from the amino acid tryptophan. The enzyme Aminocarboxymuconate Semialdehyde Decarboxylase (ACMSD) converts its substrate, ACMS, into the side branch of the pathway leading to its complete oxidation, consequently limiting the proportion of ACMS capable to generate NAD+. Since reducing ACMSD activity would prevent the flux of metabolites into the side branch and channel them towards NAD+ formation instead, the ultimate goal of this thesis was to establish the role of ACMSD in the control of the intracellular NAD+ content. First, by using genetic tools I found that reduction of ACMSD activity indeed boosts de novo NAD+ synthesis through a mechanism that is conserved from the worm C. elegans to the mouse. Beneficial effects associated with the observed increase in cellular NAD+ levels promoted mitochondrial biogenesis involving sirtuin activation. Secondly, I participated in the development of a panel of potent and selective ACMSD inhibitors. Given the restricted expression of ACMSD in the kidney and liver, its pharmacological inhibition can be a valuable strategy to increase NAD+ content in these tissues and to protect them from injury. After primary characterisation of the ACMSD inhibitors in cell models, I explored the therapeutic potential of the lead compounds to protect from non-alcoholic fatty liver disease and acute kidney injury in mice. Collectively, the data reported in this thesis describe ACMSD as an evolutionary conserved modulator of cellular NAD+ levels, sirtuin activity and mitochondrial homeostasis. Through its impact on cellular NAD+ levels ACMSD inhibition is able to preserve the hepatic and renal function from injury.

EPFL2017

Chargement

EPFL2017